Analyzing Grafton Group (OTCMKTS:GROUF) & Zealand Pharma A/S (OTCMKTS:ZLDPF)

Grafton Group (OTCMKTS:GROUF) and Zealand Pharma A/S (OTCMKTS:ZLDPF) are both mid-cap construction companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.

Insider & Institutional Ownership

8.2% of Grafton Group shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Grafton Group has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500. Comparatively, Zealand Pharma A/S has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500.

Valuation and Earnings

This table compares Grafton Group and Zealand Pharma A/S”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grafton Group	$2.51 billion	1.12	$185.00 million	N/A	N/A
Zealand Pharma A/S	$49.75 million	106.38	-$102.18 million	($2.43)	-42.28

Grafton Group has higher revenue and earnings than Zealand Pharma A/S.

Profitability

This table compares Grafton Group and Zealand Pharma A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Grafton Group	N/A	N/A	N/A
Zealand Pharma A/S	-1,375.16%	-18.49%	-16.57%

Analyst Ratings

This is a summary of recent recommendations for Grafton Group and Zealand Pharma A/S, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grafton Group	0	0	0	0	0.00
Zealand Pharma A/S	0	0	3	0	3.00

Summary

Grafton Group beats Zealand Pharma A/S on 6 of the 10 factors compared between the two stocks.

About Grafton Group

Grafton Group plc engages in the distribution, retailing, and manufacturing businesses in Ireland, the Netherlands, Finland, and the United Kingdom. Its Distribution segment distributes building materials, paint, tools, ironmongery, fixings, and accessories, workwear and PPE, and spare parts; materials and plant for mechanical services, heating, plumbing, and air movement; and trade, DIY, and self-build markets with building materials, timber, doors and floors, plumbing and heating, bathrooms, and landscaping products under the Selco, Leyland SDM, Chadwicks, MacBlair, Isero, Polvo, Gunters en Meuser, TG Lynes, and IKH brands. The company’s Retailing segment retails home and garden products through stores, including DIY products, paints, lighting products, homestyle products, housewares, bathroom products, and kitchens, as well as gardening and Christmas products under the Woodie’s brand. Its Manufacturing segment manufactures dry mortars and wooden staircases; and drainage, ducting and roofline systems under the CPI Mortar, StairBox, and MFP brand names. Grafton Group plc was founded in 1902 and is based in Dublin, Ireland.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.